OSN New York and OSN New York Retina

OSN New York and OSN New York Retina

January 07, 2020
11 min watch

VIDEO: Should SLT be the preferred first-line treatment?

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW YORK — In her presentation at OSN New York 2019, Valerie Trubnik, MD, FACS, discusses results of the LiGHT trial, which compared selective laser trabeculoplasty and eye drop treatment for mild to moderate glaucoma.